$241 Million is the total value of Virtus ETF Advisers LLC's 355 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CNX | Exit | CNX RES CORP | $0 | – | -1,290 | -100.0% | -0.01% | – |
| DEN | Exit | DENBURY INC | $0 | – | -777 | -100.0% | -0.01% | – |
| CRBP | Exit | CORBUS PHARMACEUTICALS HLDGS | $0 | – | -44,601 | -100.0% | -0.04% | – |
| MVC | Exit | MVC CAP INC | $0 | – | -27,393 | -100.0% | -0.11% | – |
| ASMB | Exit | ASSEMBLY BIOSCIENCES INC | $0 | – | -14,760 | -100.0% | -0.13% | – |
| OVID | Exit | OVID THERAPEUTICS INC | $0 | – | -58,716 | -100.0% | -0.18% | – |
| MYOK | Exit | MYOKARDIA INC | $0 | – | -3,282 | -100.0% | -0.23% | – |
| CLVS | Exit | CLOVIS ONCOLOGY INC | $0 | – | -86,459 | -100.0% | -0.26% | – |
| RTRX | Exit | RETROPHIN INC | $0 | – | -38,150 | -100.0% | -0.37% | – |
| SGEN | Exit | SEATTLE GENETICS INC | $0 | – | -3,867 | -100.0% | -0.40% | – |
| AKCA | Exit | AKCEA THERAPEUTICS INC | $0 | – | -43,813 | -100.0% | -0.42% | – |
| WPG | Exit | WASHINGTON PRIME GROUP NEW | $0 | – | -1,310,912 | -100.0% | -0.44% | – |
| MNTA | Exit | MOMENTA PHARMACEUTICALS INC | $0 | – | -18,823 | -100.0% | -0.52% | – |
| VIV | Exit | TELEFONICA BRASIL SAsponsored adr | $0 | – | -131,266 | -100.0% | -0.53% | – |
| AIV | Exit | APARTMENT INVT & MGMT COcl a | $0 | – | -32,760 | -100.0% | -0.58% | – |
| AIMT | Exit | AIMMUNE THERAPEUTICS INC | $0 | – | -32,688 | -100.0% | -0.59% | – |
| IMMU | Exit | IMMUNOMEDICS INC | $0 | – | -18,897 | -100.0% | -0.84% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC | 31 | Q3 2023 | 1.7% |
| REGENERON PHARMACEUTICALS | 31 | Q3 2023 | 1.8% |
| INCYTE CORP | 31 | Q3 2023 | 2.1% |
| ENANTA PHARMACEUTICALS INC | 31 | Q3 2023 | 2.2% |
| EXELIXIS INC | 31 | Q3 2023 | 1.8% |
| VANDA PHARMACEUTICALS INC | 31 | Q3 2023 | 1.7% |
| IRONWOOD PHARMACEUTICALS INC | 31 | Q3 2023 | 2.0% |
| LIGAND PHARMACEUTICALS INC | 31 | Q3 2023 | 1.5% |
| GILEAD SCIENCES INC | 31 | Q3 2023 | 1.6% |
| HALOZYME THERAPEUTICS INC | 31 | Q3 2023 | 1.7% |
View Virtus ETF Advisers LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-15 |
| 13F-HR | 2023-11-07 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-15 |
View Virtus ETF Advisers LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.